J&J's tapentadol ER tablets get FDA complete response letter
This article was originally published in Scrip
Johnson & Johnson has received a complete response letter from the US FDA for its NDA for tapentadol extended-release tablets. The application seeks approval to market the drug as an oral analgesic for the management of moderate to severe chronic pain in patients aged 18 years or older.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.